Divalproex Sodium Delayed Release Tablets Articles
Abbott Lab’s 4th-quarter 2009 profit flat due to charges, buts sales rise nearly 11% driven by Humira; still open to buys
28 January 2010
US Justice Department probing Abbott Lab’s Depakote marketing
9 November 2009
53% jump in 1st-qtr profit for Abbott
15 April 2009
Final appro for Mylan's generic Depakote
9 February 2009
Abbott's 4th-qtr profit jumps 28% on strong sales of Humira and divestment of spinal products unit
26 January 2009
Anti-epileptics to get suicide warnings in USA
22 December 2008
Upsher-Smith launches generic Depakote
8 September 2008
FDA approves generic Depakote
11 August 2008
Abbott Labs returns to profit in 4th-qtr 2007
28 January 2008
Patent expiry for 2008 provides generic opportunity
14 January 2008
Tentative FDA appro for Noven's Stavzor
7 January 2008
Noven gets FDA "approvable letter" for Stavzor
29 October 2007
Abbott Labs' 2nd-qtr 2007 profit soars 61.4%
23 July 2007
Abbott's 1st-qtr profit drops 19% to $697.5M
23 April 2007
Abbott suffers 4th-qtr $0.37 LPS on Kos buy
5 February 2007
Abbott's 2nd qtr profit drops on Guidant buy
24 July 2006
FDA expands indiction of Abbott's Depakote ER
12 December 2005
Abbott sees 13.9% rise in sales for 1st-qtr 2004
19 April 2004
Abbott's rare win over generics firm
29 March 2004
Abbott wins Depakote patent sut against TorPharm
22 March 2004
Abbott reports sharp rise in 4-qtr profit
26 January 2004
Abbott earnings up as core sales grow
20 October 2003
Abbott earnings up as core sales grow
20 October 2003
New NICE guidances for England and Wales
6 October 2003
Abbott's Depakote ER gets FDA clearance for pediatric use
15 September 2003
Lilly gains FDA OK for new Zyprexa use
21 July 2003
US FDA OKs Andrx generic valproate
24 March 2003
Abbott's profits up 2%, forecasts lowered
27 January 2003
Abbott gets approval for blockbuster candidate Humira in USA
6 January 2003
Abbott gains FDA OK for once-daily Depakote
6 January 2003
Abbott posts strong revenue growth for 2001, but charges hit
21 January 2002
Lilly reports successful Zyprexa trials
15 October 2001
Abbott sales up 26% though earnings slip
11 October 2001
Abbott sales up 26% though earnings slip
10 October 2001
Abbott sales growth driven by pharma
13 July 2001
FDA's tentative OK for generic Depakote
8 June 2001
US pharma business driving Abbott
17 April 2001
US pharma business driving Abbott
12 April 2001
Abbott gives up US Gabitril rights
3 November 2000
Abbott strengthens label for epilepsy drugs
7 August 2000
Abbott 1998 sales reach $12.5 billion
18 January 1999
Abbott Labs Impacted By Strength Of Dollar
14 July 1998
Abbott's Depakote Overtakes Lithium For Mania
4 June 1998
Drug Delivery Sales "To Grow 15% A Year To 2005"
4 February 1998
Migraine Market Hotting Up In The USA
20 January 1998
Epilepsy Market Sees Strong Growth
29 July 1997
US 4th Qtr/Year-End Results See Strong Growth
27 January 1997
Higher-Priced Drugs Set To Expand Epilepsy Market
12 February 1996
Strong International Sales For US Cos In 2nd Qtr
31 July 1995
Abbott's Divalproex Gains 3rd Indication In USA
12 June 1995
Abbott's Depakote is approvable
5 June 1995
FDA Panel Backs Abbott's Depakote For Bipolar Illness
13 February 1995
Abbott's AIDS Drug In Phase I/II Studies
24 October 1994
Abbott Submits NDA For Zileuton
26 September 1994
Abbott Approvals In USA
12 September 1994
ABBOTT'S DEPAKOTE FOR BIPOLAR ILLNESS
4 April 1994
ABBOTT CAN PRODUCE "RESPECTABLE EARNINGS GROWTH"
23 August 1993
ABBOTT ACHIEVES RECORD SALES
19 April 1993
NEW DRUGS FOR EPILEPTICS
13 January 1992
Showing 1-77 of 77 articles
- 1
- Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
- Elan makes "transformational" acquisitions and a divestment
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
- Is failure to adopt business process management putting the pharma industry at risk?
- Greek research-based drugmaker group AIFD challenges generics assumptions in Draft Patent Law
